Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). NANOPULSE-AF surpassed enrollment midpoint after beginning in April 2026.
PULSE BIOSCIENCES, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- NANOPULSE-AF surpassed enrollment midpoint after beginning in April 2026
- Pivotal multicenter study evaluating nPulse™ Cardiac Catheter System for recurrent, drug-resistant symptomatic paroxysmal atrial fibrillation
- Enrollment planned at up to 30 sites, including locations outside the United States
- Milestone supports potential progression toward regulatory submission, but clinical efficacy and safety results remain pending
Item EX-99.1 · Exhibit EX-99.1
- NANOPULSE-AF pivotal IDE study surpassed enrollment midpoint after starting in April 2026
- Rapid enrollment supports investigator interest and may accelerate completion of U.S. pivotal testing
- Study targets nPulse System evaluation for atrial fibrillation treatment and pulmonary vein isolation
- Management scheduled additional study-progress commentary for August 6 earnings conference call
- Clinical efficacy and safety remain unproven pending full pivotal-study results and FDA review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PULSE BIOSCIENCES, INC. 8-K filings
Get the next PLSE 8-K as it lands
Follow PLSE for push alerts, or ask the research agent what this filing means.